Keros discontinues cibotercept development, prioritizes KER-065; CEO becomes President, COO departs

Keros Therapeutics, Inc.

Discontinuing all internal development of cibotercept (KER-012) after PAH trial termination.
Exclusively prioritizing KER-065 for Duchenne muscular dystrophy; Phase 2 expected Q1 2026.
CEO Jasbir Seehra adds President role effective Aug 18, 2025; steps down as Board Chair.
Jean-Jacques Bienaimé appointed Chair of the Board, effective Aug 18, 2025.
COO Christopher Rovaldi to depart Aug 18; Lorena Lerner promoted to CSO; SVP roles eliminated.

item 5.02item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.